The HPRT1 Knouckout A-549 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population targeting the HPRT1 gene in the A-549 cell line. This loss-of-function model is generated through CRISPR/Cas9-mediated gene disruption, yielding a heterogeneous pool of edited cells. The product is designed for studying HPRT1 deficiency without the need for clonal isolation, offering a practical tool for examining purine salvage pathway defects in a lung adenocarcinoma background.
The parental A-549 cell line is an immortalized epithelial model derived from lung adenocarcinoma tissue of a 58-year-old Caucasian male. These cells display alveolar type II epithelial characteristics, including lamellar body formation and surfactant production, and are a standard in vitro system for lung cancer biology. Their stable karyotype and tractability to genetic manipulation make them well-suited for CRISPR-mediated knockout studies.
HPRT1 functions as a purine salvage enzyme, catalyzing the conversion of hypoxanthine to IMP and guanine to GMP using PRPP as the phosphoribosyl donor. The enzyme is regulated by substrate availability of hypoxanthine and guanine, and it interacts with components of the PRPP synthetase complex. Within the purine salvage pathway, HPRT1 acts alongside APRT, ADA, and PNP. The reaction produces IMP, GMP, and pyrophosphate, directly contributing to cellular purine nucleotide pools. Disruption of HPRT1 removes this salvage capacity, shifting nucleotide biosynthesis toward de novo pathways and potentially perturbing nucleotide homeostasis.
In the A-549 lung adenocarcinoma context, HPRT1 knockout creates a metabolic model where purine supplies depend solely on de novo synthesis. This alteration is relevant for exploring metabolic reprogramming in cancer cells, as nucleotide metabolism is closely linked to proliferation. The knockout phenotype also confers resistance to purine analogs like 6-thioguanine, enabling its use as a selection marker and for studying mechanisms of drug resistance. Consequently, this model provides a platform to investigate nucleotide imbalances and their impact on tumor cell growth.
This polyclonal knockout product is applicable across diverse experimental settings, including purine metabolism studies, disease modeling of Lesch-Nyhan and Kelley-Seegmiller syndromes, and hyperuricemia research. Standard characterization methods include western blotting, RT-qPCR, and Sanger sequencing to confirm gene disruption, while functional validation can be performed using 6-thioguanine cytotoxicity assays and HPRT enzymic activity measurements. Additional uses encompass nucleotide pool quantification and proliferation assays, supporting investigations into nucleotide-dependent growth control and anticancer drug responses. For further information, please contact Ascent Research.
